insights_auto
Pourquoi 4142 a-t-elle baissé de 6,62%?
Approfondirchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
-6,62%(-1,05) 1J
20 nov., 13:30:09 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
15,75 TWD
Élevé
15,75 TWD
Faible
14,80 TWD
Cap. boursière
6,36 Md
Vol. moyen
1,13 M
Volume
1,63 M
Ratio cours/bénéfice
85,76
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
14,80 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Ouverture
15,75 TWD
Élevé
15,75 TWD
Faible
14,80 TWD
Cap. boursière
6,36 Md
Vol. moyen
1,13 M
Volume
1,63 M
Ratio cours/bénéfice
85,76
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
14,80 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
AP News
·
il y a 2 heures
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
The Motley Fool
·
il y a 37 minutes
Report: Goldman Sachs Predicts the S&P 500 Will Gain 26% in 12 Months
WSJ
·
il y a 15 heures
S&P 500 Flirts With Correction
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp